Hiroe Toki

Title: Hiroe Toki: Innovator in Antibody Development

Introduction

Hiroe Toki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, Toki's work focuses on innovative solutions for treating and diagnosing diseases related to the system ASC amino acid transporter 2 (ASCT2).

Latest Patents

Toki's latest patents include a DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody. This invention aims to provide a monoclonal antibody that is useful for treating or diagnosing diseases associated with ASCT2. The patent details a monoclonal antibody that specifically recognizes the native three-dimensional structure of the extracellular region of ASCT2 and binds to it. Additionally, the patent covers a hybridoma that produces the antibody, a DNA encoding the antibody, a vector containing the DNA, and a process for producing the antibody or its fragments. Furthermore, it outlines the therapeutic and diagnostic agents that utilize this antibody.

Career Highlights

Hiroe Toki is currently associated with Kyowa Hakko Kirin Co., Limited, a leading biopharmaceutical company. His work at the company has been instrumental in advancing research and development in antibody therapies. Toki's innovative approach has positioned him as a key figure in the biotechnology sector.

Collaborations

Toki collaborates with notable colleagues, including Norihiko Shiraishi and Akiko Furuya. Their combined expertise contributes to the success of their projects and enhances the research environment at Kyowa Hakko Kirin Co., Limited.

Conclusion

Hiroe Toki's contributions to the field of biotechnology, particularly in monoclonal antibody development, highlight his role as an influential inventor. His innovative patents and collaborations continue to pave the way for advancements in medical treatments.